Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex) in Patients at High Risk of Carrying Blood Diseases

Next Previous
Trial Profile

Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex) in Patients at High Risk of Carrying Blood Diseases

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Antithymocyte globulin; Fludarabine
  • Indications Haematological malignancies
  • Focus Therapeutic Use

Most Recent Events

  • 10 Dec 2019 Results evaluating two conditioning groups: BxPK: n=27; PK-guided busulfan conditioning regimen from NCT02483325 study and BxPK: n=56; a retrospectively enrolled control cohort of patients with same inclusion criteria, assessing wheteher pharmacokinetics guided strategy improve the safety of busulfan were presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
  • 22 Jan 2019 Status changed from recruiting to completed.
  • 07 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top